Suzhou, October 28, 2022 - Alphamab Oncology (stock code: 9966.HK) announced the IND application to conduct a Phase Ia/Ib Clinical Trial of Anti-HER2 bispecific ADC was approved by the Center for Drug Evaluation (CDE) of NMPA. The study will evaluate the safety and tolerability of JSKN003 in Chinese patients with advanced malignant solid tumors, and to determine the maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D).
According to the latest report released by the National Cancer Center in 2022, the incidence of cancer in China continues to rise, with more than 11,100 people are diagnosed with tumors every day, among which lung cancer, colorectal cancer, gastric cancer, liver cancer and female breast cancer account for 57.4% of the total new cases. Human epidermal growth factor receptor-2 (HER2) is an effective target for the treatment of a variety of advanced malignant solid tumors, and antibody-drug conjugates (ADCs) have been shown to significantly improve the clinical efficacy. Therefore, exploring novel HER2-targeting antibody-drug conjugates could provide new treatment options for more cancer patients.
JSKN003 is an anti-HER2 bispecific antibody-drug conjugate (ADC), which is developed inhouse with proprietary Glycan-specific conjugation platform. Through enzyme catalysis and click chemistry, the payloads are site-specifically linked to glycan on Fc. The glycan structure is precisely controlled via process engineering which renders consistant DAR with more favorable stability. Compared other ADC drugs, JSKN003 induce faster and more intense endocytosis, which leads to stronger bystander effect in HER2-expressing tumors. Meanwhile the better serum stability ensures much wider therapeutic window. For example, JSKN003 shows better safety profile in preclinical study and comparable tumor killing activity with Enhertu (DS-8201) in both high and low HER2 expression (CDX+PDX model). A phase I clinical dose escalation study in underway in Australia for JSKN003 and the first patient was dosed in September 2022.
About JSKN003
JSKN003 is an anti-HER2 bispecific antibody-drug conjugate (ADC), which is developed inhouse with proprietary Glycan-specific conjugation platform. JSKN003 targets HER2 and triggers a signal in the tumor cell, which then internalizes the antibody together with the payload. After endocytosis, the cytotoxic drug is released and kills the cancer cells. Compared other ADC drugs, JSKN003 induce faster and more intense endocytosis, which leads to stronger bystander effect in HER2-expressing tumors. Meanwhile the better serum stability ensures much wider therapeutic window. A Phase I, multicenter, open-label, dose-escalation, first-in-human trial in Australia is ongoing to assess safety and tolerability in patients with advanced or metastatic solid malignancies and to determine the maximum tolerated dose /RP2D. The phase I clinical study application of JSKN003 in China for treatment of advanced solid tumors was approved by NMPA.
About Alphamab Oncology
Alphamab Oncology is a leading biopharmaceutical company dedicated to the discovery, development manufacturing and commercialization of world-class innovative biotherapeutics for cancer treatment. On December 12, 2019, Alphamab Oncology was listed on the Main Board of Hong Kong Stock Exchange, with the stock code:9966.
We have converged a professional R&D team led by top scientists, and have a complete industrial chain from early research and development of innovative drugs, process development, commercial production to clinical research.
With multiple in-house proprietary platforms of bispecifics, protein engineering and antibody screening, Alphamab Oncology has established a globally competitive and differentiated pipeline which consists of tumor monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates. Among them, 2 varieties were selected into the national special project of " New Drug Development", and 3 varieties were granted 4 orphan drug qualifications by FDA. The world's first subcutaneous PD-L1 inhibitor injection (Envafolimab) has been obtained the market approval by the Chinese National Medical Products Administration. More than 30 clinical studies have been carried out in 6 varieties in China, the United States and Australia, among which 8 studies of 3 varieties have entered the critical clinical stage in China and the United States.
To make cancer manageable and curable，Alphamab Oncology has always been guided by clinical value and patient needs, and focuses on the development of innovative, safe and affordable anti-tumor drugs to benefit patients in China and around the world.
Alphamab Oncology Forward-Looking Statements
This press release contains statements related to our future business， financial performance and future events involving Alphamab Oncology that may constitute forward-looking statements. These statements include projections and estimates and relevant assumptions, statements regarding plans and expectations and statements regarding future activities, operations and performance. These statements may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," or words of similar meaning. Such statements are based on the certain assumptions of Alphamab Oncology’s management and business operations, which are subject to various risks and uncertainties, including but not limited to political, economic, legal and business environment. The actual results, performance or achievements of Alphamab Oncology may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statements. Unless otherwise required by applicable laws, Alphamab Oncology does not undertake obligation to publicly update any forward-looking statement nor liability for the failure to materialize such forward-looking statements, whether because of new information, future events or otherwise.
